David Arrington | SVP of IR and Corporate Affairs |
Mark Goldsmith | Chairman and CEO |
Jack Anders | SVP, Finance and Principal Accounting Officer |
Steve Kelsey | President, Research and Development |
Marc Frahm | Cowen & Company |
Alec Stranahan | Bank of America |
Jonathan Chang | SVB Securities |
Neil Carnahan | Stifel |
Noah Eisenberg | JPMorgan Chase |
Good day. My name is Christie, and I'll be your conference facilitator today. Welcome to the Revolution Medicines Second Quarter 2022 Earnings Conference Call. Today's call is being recorded. [Operator Instructions] I would now like to hand the conference over to David Arrington, Revolution Medicines' SVP of Investor Relations and Corporate Affairs for opening remarks.